CME

Jan 23 2025 486 ep. 88

CME Podcast artwork

Copy RSS

Subscribe on Podcast Addict

Masterclass in Cardiac Amyloidosis: Disease Spectrum, Diagnosis, and Management

Host: Saurabh Malhotra, MD, MPH Guest: Kevin Alexander, MD Guest: Tawfiq Al-lahham, MD Guest: Sarah Cuddy, MD Guest: Angela Dispenzieri, MD Guest: Anita D’Souza, MD Guest: Foluso Fakorede, MD Guest: Mazen Hanna, MD Guest: Isabelle Lousada Guest: Ahmad Masri, MD, MS Guest: Mathew S. Maurer, MD Guest: Matthew Parker, MD Guest: Frederick Ruberg, M

Beyond the Symptoms: The True Impact of gMG on Patients' Lives

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn recept

Understanding Disease Progression: The Shift From Ocular to Generalized MG

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn recept

Life-Threatening Events: Understanding and Preventing Myasthenic Crisis

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn recept

Diagnosing gMG: Navigating Current Tools and Approaches

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn recept

Autoantibodies in MG: Their Role in Diagnosis and Treatment

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn recept

Balancing Risk and Benefit: Traditional MG Treatments and Medications to Avoid

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn recept

The Science Behind FcRn Antagonists: A Deep Dive Into Their Mechanism of Action

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn recept

FcRn Antagonists in Myasthenia Gravis: A New Era in Targeted Therapy

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn recept

Optimizing FcRn Therapy: Addressing and Reducing Adverse Reactions

Guest: Nicholas J. Silvestri, MD, FAAN Guest: James F. Howard, Jr, MD The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn recept